Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 12 | Journal of Biology

Figure 12

From: CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo

Figure 12

Co-analysis of BrdU incorporation with antigen expression indicates that division of both DCX+ neuronal progenitors and Olig2+ oligodendrocyte precursors is reduced by systemic exposure to cytarabine. In the CC, where there was an approximately 50% reduction in the number of BrdU+ cells (see Figure 11b), the proportion of BrdU+ cells that were Olig2+ was no different between controls and treated animals on either day 1 ((a) control; (b) cytarabine) or on day 56 ((c) control; (d) cytarabine) after completion of treatment. Thus, the reduction in apparent division of Olig2+ cells was proportionate to the overall reduction in all BrdU+ cells. In contrast with effects on Olig2+ populations in the corpus callosum, our analyses indicate an enhanced loss of DCX+ cells from among the BrdU+ population in both the SVZ and DG. This was particularly striking in the DG, where at 56 days post-treatment the proportion of BrdU+ cells in the cytarabine-treated animals was < 40% of that seen in control animals. Data are means ± SEM; *P < 0.05, **P < 0.01, and ***P < 0.001 in comparisons with control animals.

Back to article page